Discover 2,450 paid clinical trials in North Carolina. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
From paid studies for healthy volunteers to condition-specific trials, North Carolina offers a wide range of clinical research opportunities. Leading medical centers in Charlotte, Raleigh, and Durham are seeking participants, providing access to innovative treatments and comprehensive care.
Filter
1
Filter results
Results: 2,450
Registry Study for Radiation Therapy Outcomes
for
Neoplasms
Location: New York NY, Somerset NJ, Hampton VA, Baltimore MD,
Sponsor: Proton Collaborative Group
Sex: All
Age: 0+
Code: NCT01255748
Recruiting
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Brewer ME, Manchester NH, Worcester MA, Concord NH,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 0+
Code: NCT06031688
Phase2, Recruiting
Engage Psychosocial Intervention for Cancer Symptoms
for
Advanced Breast Cancer, Advanced Prostate Cancer,
Location: Durham NC
Sponsor: Duke University
Sex: All
Age: 18+
Code: NCT06555588
Recruiting
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
for
Relapsed Hematologic Malignancy,
Location: Boston MA, New York NY, Durham NC, Buffalo NY,
Location: Hartford CT, New York NY, Philadelphia PA, Norfolk VA,
Sponsor: Endospan Ltd.
Sex: All
Age: 18+
Code: NCT04471909
Recruiting
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
for
Peripheral T-Cell Lymphoma, Not Otherwise Specified,
Location: Boston MA, New Haven CT, New York NY, Hackensack NJ,
Sponsor: Corvus Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT06561048
Phase3, Recruiting
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
for
Low Grade Astrocytoma, Low Grade Glioma,
Location: St. John's, Halifax, Bangor ME, Scarborough ME,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 2 - 21
Code: NCT04166409
Phase3, Recruiting
NMES and Chronic Ankle Instability
for
Chronic Ankle Instability
Location: Boone NC
Sponsor: Appalachian State University
Sex: All
Age: 18 - 35
Code: NCT04322409
Phase1, Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
for
Heart Failure
Location: Bridgeport CT, The Bronx NY, New York NY,
Sponsor: Boehringer Ingelheim
Sex: All
Age: 18+
Code: NCT06424288
Phase3, Recruiting
Beat Childhood Cancer Specimen Banking and Data Registry
for
Pediatric Cancer, Survivorship
Location: Hartford CT, Norfolk VA, Hershey PA, Miami FL,
Sponsor: Giselle Sholler
Sex: All
Age: 0+
Code: NCT04715178
Recruiting
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Location: New York NY, Philadelphia PA, Durham NC, Miami FL,
Sponsor: Fate Therapeutics
Sex: All
Age: 12 - 70
Code: NCT06308978
Phase1, Recruiting
First In Human Study of CX-2051 in Advanced Solid Tumors
for
Solid Tumor, Adult
Location: Boston MA, The Bronx NY, Fairfax VA, Huntersville NC,
Sponsor: CytomX Therapeutics
Sex: All
Age: 18+
Code: NCT06265688
Phase1, Recruiting
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
for
AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar,
Location: Boston MA, New Haven CT, Stony Brook NY,
Sponsor: Kura Oncology, Inc.
Sex: All
Age: 18+
Code: NCT06001788
Phase1, Recruiting
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
for
T-Cell Neoplasm, Lymphoproliferative Disorders
Location: Durham NC, Columbus OH, Ann Arbor MI, Duarte CA
Sponsor: University of Michigan Rogel Cancer Center
Sex: All
Age: 18+
Code: NCT04858256
Phase2, Recruiting
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma